Publications (38) Publications de MARÍA DE LAGARDE SEBASTIÁN

2024

  1. Life expectancy of people with HIV on antiretroviral therapy in Spain

    AIDS, Vol. 38, Núm. 3, pp. 387-395

2023

  1. Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens

    The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 11, pp. 2696-2701

2022

  1. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

  2. Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019

    HIV Medicine, Vol. 23, Núm. 7, pp. 705-716

  3. Incidence and Severity of SARS-CoV-2 Infection in HIV-Infected Individuals during the First Year of the Pandemic

    Journal of Acquired Immune Deficiency Syndromes, Vol. 89, Núm. 5, pp. 511-518

  4. Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance

    Open Forum Infectious Diseases, Vol. 9, Núm. 11

2021

  1. Blood Bacterial Profiles Associated With Human Immunodeficiency Virus Infection and Immune Recovery

    The Journal of infectious diseases, Vol. 223, Núm. 3, pp. 471-481

  2. Different HCV exposure drives specific miRNA profile in PBMCS of HIV patients

    Biomedicines, Vol. 9, Núm. 11

2020

  1. How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain

    HIV Medicine, Vol. 21, Núm. 2, pp. 128-134

  2. Sustained virological response at week 12 after interferon-free therapy as criterion for HCV cure definition: Validation in a real-life cohort of HIV-coinfected patients

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 6, pp. 275-278

2019

  1. Effects of immunonutrition in advanced human immunodeficiency virus disease: A randomized placebo-controlled clinical trial (Promaltia study)

    Clinical Infectious Diseases, Vol. 68, Núm. 1, pp. 120-130

  2. HCV eradication with all-oral therapy in cirrhotic HIV-coinfected patients: an observational study of early changes in liver function and fibrosis tests

    Revista Española de Enfermedades Digestivas, Vol. 111, Núm. 8, pp. 626-632

  3. HCV-coinfection is related to an increased HIV-1 reservoir size in cART-treated HIV patients: a cross-sectional study

    Scientific Reports, Vol. 9, Núm. 1

  4. Predictive factors of hepatitis C virus eradication after interferon-free therapy in HIV coinfection

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 38, Núm. 4, pp. 725-734

  5. Rhodomyrtone decreases Staphylococcus aureus SigB activity during exponentially growing phase and inhibits haemolytic activity within membrane vesicles

    Microbial Pathogenesis, Vol. 128, pp. 112-118

2018

  1. Erratum: Effects of immunonutrition in advanced human immunodeficiency virus disease: A randomized placebo-controlled clinical trial (Promaltia study) (Clinical Infectious Diseases DOI: 10.1093/cid/ciy414)

    Clinical Infectious Diseases

  2. Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients

    Medicine (United States), Vol. 97, Núm. 38

  3. Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment

    Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337

  4. Persistently altered liver test results in hepatitis C patients after sustained virological response with direct-acting antivirals

    Journal of Viral Hepatitis, Vol. 25, Núm. 7, pp. 818-824

2017

  1. Dual Therapy with Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy with Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial

    Clinical Infectious Diseases, Vol. 65, Núm. 12, pp. 2112-2118